Abstract
Heroin administered i.c.v. acts on supraspinal μ opioid receptors in ICR mice but on δ receptors in Swiss Webster mice. The purpose of this study was to determine the degree to which genotype plays a role in the opioid receptor selectivity of heroin across a range of fully inbred strains of mice. Six inbred strains were given heroin i.c.v. 10 min before the tail-flick test. Differences in the descending neurotransmitter systems involved in supraspinal opioid-induced analgesia were evaluated as the first step. Antagonism by bicuculline given intrathecally indicated the involvement of supraspinal δ receptors in activating spinal γ-aminobutyric acid (GABA) receptors; antagonism by intrathecal methysergide indicated either μ or κ receptor involvement. Antagonism by intrathecal yohimbine implicated μ and eliminated κ receptor involvement. Intracerbroventricular opioid antagonists (β-funaltrexamine, 7-benzylidenenaltrexone, naltriben, or nor-binaltorphimine) provided further differentiation. Based on these initial results, receptor selectivity was determined by more extensive ED50experiments with i.c.v. administration of heroin with opioid antagonists, β-funaltrexamine (for μ), naltrindole (for δ), and nor-binaltorphimine (for κ). The combined results indicated that heroin analgesia was predominantly mediated in C57BL/6J by δ, in DBA/2J and CBA/J by μ, and in BALB/cByJ and AKR/J by κ receptors. The response in C3H/HeJ appeared to involve μ receptors. The results indicate that the opioid receptor selectivity of heroin is genotype-dependent. Because these genotypes are fully inbred, the genetically determined molecular and neurochemical substrate mediating the different opioid receptor selectivities of heroin can be studied further.
Footnotes
-
Send reprint requests to: Janes M. Fujimoto, Ph.D., Research Service 151, Veterans Affairs Medical Center, Milwaukee, WI 53295-0001.
-
1 This work was supported by Grant DA00451 from the National Institute on Drug Abuse and was also supported by the Department of Veterans Affairs Medical Research Fund and the National Institute on Drug Abuse Addiction Research Center.
- Abbreviations:
- DPDPE
- (D-Pen2,5)enkephalin
- DAMGO
- Tyr-d-Ala2-Gly-N-MePhe4-Gly-ol5
- U50
- 488H,trans-+-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzene acetamide methanesulfonate
- β-FNA
- β-funaltrexamine
- BNTX
- 7-benzylidenenaltrexone
- N-BNI
- nor-binaltorphimine
- GABA
- γ-aminobutyric acid
- % MPE
- percent maximum possible effect
- i.c.v.
- intracerebroventricular(ly)
- IT
- intrathecal(ly)
- Received April 8, 1998.
- Accepted August 28, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|